Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fan Bu

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Biorxiv : the Preprint Server for Biology|April 15, 2026
A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformationHuihui Mou, Bo Gao, Gang Ye, et al.
Diabetes Care|June 4, 2025
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort StudyDaniel R Morales, Fan Bu, Benjamin Viernes, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Ophthalmology. Retina|March 22, 2024
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network StudyCindy X Cai, Akihiko Nishimura, Mary G Bowring, et al.
BMJ Open Diabetes Research & Care|November 5, 2025
Semaglutide and diabetic retinopathy: an OHDSI network studyCindy Xinji Cai, Akihiko Nishimura, Sally Baxter, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
JAMA Ophthalmology|February 20, 2025
Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyCindy X Cai, Michelle Hribar, Sally Baxter, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudyRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Biorxiv : the Preprint Server for Biology|April 15, 2026
A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformationHuihui Mou, Bo Gao, Gang Ye, et al.
Diabetes Care|June 4, 2025
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort StudyDaniel R Morales, Fan Bu, Benjamin Viernes, et al.
Medrxiv : the Preprint Server for Health Sciences|May 19, 2025
Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DMChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Nature Communications|April 4, 2026
Real-world evidence for comparative safety of second-line antihyperglycemic agents in older adults with type 2 diabetesChungsoo Kim, Fan Bu, Clair Blacketer, et al.
Ophthalmology. Retina|March 22, 2024
Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network StudyCindy X Cai, Akihiko Nishimura, Mary G Bowring, et al.
BMJ Open Diabetes Research & Care|November 5, 2025
Semaglutide and diabetic retinopathy: an OHDSI network studyCindy Xinji Cai, Akihiko Nishimura, Sally Baxter, et al.
BMJ Medicine|October 13, 2023
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Lovedeep Singh Dhingra, Arya Aminorroaya, et al.
Journal of the American College of Cardiology|August 28, 2024
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DMRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
JAMA Ophthalmology|February 20, 2025
Semaglutide and Nonarteritic Anterior Ischemic Optic NeuropathyCindy X Cai, Michelle Hribar, Sally Baxter, et al.
Medrxiv : the Preprint Server for Health Sciences|February 19, 2024
Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudyRohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, et al.
Pageof 25